Detailed information for compound 174785

Basic information

Technical information
  • TDR Targets ID: 174785
  • Name: N-[(E)-[5-(3-chloro-4-methylphenyl)furan-2-yl ]methylideneamino]-4-hydroxy-3-methoxybenzami de
  • MW: 384.813 | Formula: C20H17ClN2O4
  • H donors: 2 H acceptors: 2 LogP: 4.5 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1cc(ccc1O)C(=O)N/N=C/c1ccc(o1)c1ccc(c(c1)Cl)C
  • InChi: 1S/C20H17ClN2O4/c1-12-3-4-13(9-16(12)21)18-8-6-15(27-18)11-22-23-20(25)14-5-7-17(24)19(10-14)26-2/h3-11,24H,1-2H3,(H,23,25)/b22-11+
  • InChiKey: JEZLJEFWKHUIFU-SSDVNMTOSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • N-[(E)-[5-(3-chloro-4-methyl-phenyl)-2-furyl]methyleneamino]-4-hydroxy-3-methoxy-benzamide
  • N-[(E)-[5-(3-chloro-4-methylphenyl)-2-furyl]methyleneamino]-4-hydroxy-3-methoxybenzamide
  • N-[(E)-[5-(3-chloro-4-methyl-phenyl)furan-2-yl]methylideneamino]-4-hydroxy-3-methoxy-benzamide
  • N-[[5-(3-chloro-4-methylphenyl)furan-2-yl]methylideneamino]-4-hydroxy-3-methoxybenzamide
  • N-[[5-(3-chloro-4-methyl-phenyl)-2-furyl]methyleneamino]-4-hydroxy-3-methoxy-benzamide
  • N-[[5-(3-chloro-4-methylphenyl)-2-furyl]methyleneamino]-4-hydroxy-3-methoxybenzamide
  • N-[[5-(3-chloro-4-methyl-phenyl)furan-2-yl]methylideneamino]-4-hydroxy-3-methoxy-benzamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens glucagon receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Loa Loa (eye worm) pigment dispersing factor receptor c glucagon receptor 477 aa 457 aa 25.4 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Trichomonas vaginalis beta-hexosaminidase B, putative 0.012 0.0728 0.5
Brugia malayi Glycosyl hydrolase family 20, catalytic domain containing protein 0.0192 0.1606 0.1606
Entamoeba histolytica beta-N-acetylhexosaminidase, putative 0.0192 0.1606 0.5
Loa Loa (eye worm) glycosyl hydrolase family 20 0.0192 0.1606 0.1606
Entamoeba histolytica beta-N-acetylhexosaminidase, beta subunit 0.0192 0.1606 0.5
Schistosoma mansoni aminopeptidase P homologue (M24 family) 0.088 1 1
Echinococcus granulosus beta hexosaminidase subunit beta 0.0192 0.1606 0.0948
Trichomonas vaginalis beta-hexosaminidase, putative 0.012 0.0728 0.5
Loa Loa (eye worm) hyaluronidase 0.088 1 1
Entamoeba histolytica beta-N-acetylhexosaminidase, putative 0.0192 0.1606 0.5
Echinococcus multilocularis beta hexosaminidase subunit beta 0.0192 0.1606 0.0948
Echinococcus multilocularis bifunctional protein NCOAT 0.088 1 1
Schistosoma mansoni Hyaluronidase 0.088 1 1
Trichomonas vaginalis beta-hexosaminidase, putative 0.012 0.0728 0.5
Trichomonas vaginalis beta-hexosaminidase, putative 0.012 0.0728 0.5
Echinococcus granulosus bifunctional protein NCOAT 0.088 1 1
Loa Loa (eye worm) hypothetical protein 0.0374 0.3826 0.3826
Entamoeba histolytica beta-N-acetylhexosaminidase, alpha subunit 0.0192 0.1606 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 12 uM Binding affinity for human Glucagon Receptor ChEMBL. 11543683
IC50 (binding) = 12 uM Binding affinity for human Glucagon Receptor ChEMBL. 11543683

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.